# US 2018/0023125 A1 · Systems and methods to detect rare mutations and copy number variation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023125 A1
- Document ID: US20180023125A1
- Status: Published application
- Kind: A1
- Application number: 15/669,779
- Filed: 2017-08-04
- Published: 2018-01-25
- Earliest claimed: 2012-09-04
- Assignees: Guardant Health, Inc.
- Applicants: Guardant Health, Inc.
- Inventors: AmirAli Talasaz; Helmy Eltoukhy
- Web page: https://patentgrep.com/patent/US20180023125A1

## CPC

- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 30/10: Sequence alignment; Homology search
- C12Q 1/6869: Methods for sequencing
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.

## Claims

### Claim 1

A method for detecting genetic aberrations in cfDNA (“cfDNA”) from a subject, comprising:
a) providing cfDNA molecules obtained from a bodily sample of the subject;
b) attaching to the cfDNA molecules, tags comprising barcodes having distinct barcode sequences to generate tagged parent polynucleotides, wherein at least 10% of the cfDNA is tagged by the attaching step;
c) amplifying the tagged parent polynucleotides to produce tagged progeny polynucleotides;
d) sequencing the tagged progeny polynucleotides to produce sequence reads, wherein each sequence read comprises a barcode sequence and a sequence derived from a cfDNA molecule;
e) grouping the sequence reads into families based at least on the barcode sequence;
f) comparing the sequence reads grouped within each family to determine consensus sequences for each family, wherein each of the consensus sequences corresponds to a unique polynucleotide among the tagged parent polynucleotides; and
g) detecting, at one or more genetic loci, a plurality of genetic aberrations, wherein the genetic aberrations are differently selected from: a single base substitution, a copy number variation (CNV), an indel, and a gene fusion.

### Claim 2 (depends on 1)

The method of claim 1, comprising providing less than 100 ng of the cfDNA.

### Claim 3 (depends on 1)

The method of claim 1, comprising providing less than 10 ng of the cfDNA.

### Claim 4 (depends on 1)

The method of claim 1, comprising providing between 100 and 100,000 human haploid genome equivalents of cfDNA, wherein the cfDNA molecules are tagged with between 2 and 1,000,000 unique identifiers.

### Claim 5 (depends on 1)

The method of claim 1, comprising providing between 1000 and 50,000 human haploid genome equivalents of cfDNA, wherein the cfDNA molecules are tagged with between 2 and 1,000 unique identifiers.

### Claim 6 (depends on 1)

The method of claim 1, wherein each barcode sequence is at least 5 nucleotides in length.

### Claim 7 (depends on 1)

The method of claim 1, wherein the attaching comprises tagging the cfDNA molecules with at least 10 and at most 1000 distinct barcodes.

### Claim 8 (depends on 1)

The method of claim 1, wherein the attaching comprises uniquely tagging the cfDNA molecules.

### Claim 9 (depends on 1)

The method of claim 1, wherein the attaching comprises performing blunt-end ligation or sticky end ligation.

### Claim 10 (depends on 1)

The method of claim 1, wherein the attaching comprises using more than 10× molar excess of barcode oligonucleotides as compared to the provided cfDNA molecules.

### Claim 11 (depends on 1)

The method of claim 1, wherein the attaching comprises ligating adaptors comprising barcodes to both ends of the cfDNA molecules.

### Claim 12 (depends on 1)

The method of claim 1, wherein the attaching comprises non-uniquely tagging the cfDNA molecules such that no more than 5% of the parent polynucleotides are uniquely tagged.

### Claim 13 (depends on 1)

The method of claim 1, wherein at least 30% of the cfDNA molecules are tagged by the attaching step.

### Claim 14 (depends on 1)

The method of claim 1, wherein at least 50% of the cfDNA molecules are tagged by the attaching step.

### Claim 15 (depends on 1)

The method of claim 1 further comprising selectively enriching sequences of interest prior to the sequencing.

### Claim 16 (depends on 15)

The method of claim 15, wherein the selectively enriching comprises enriching for polynucleotides mapping to a gene selected from the group consisting of: KRAS, APC, and TP53.

### Claim 17 (depends on 1)

The method of claim 1, wherein sequencing comprises massively parallel sequencing.

### Claim 18 (depends on 1)

The method of claim 1, wherein the amplified progeny polynucleotides are sequenced to produce an average of 5 to 10 sequence reads for each family.

### Claim 19 (depends on 1)

The method of claim 1, wherein the consensus sequence possesses an error rate below 0.0001%.

### Claim 20 (depends on 1)

The method of claim 1, wherein each base of the tagged parent polynucleotides has at least 99% chance of being represented by at least one sequence read.

### Claim at position 21

-30. (canceled)
